Strategic Growth Chiltern has a history as part of Fortrea with expansion in oncology, anti-infectives/vaccines and ophthalmology, indicating cross-disciplinary capabilities to support emerging biopharma programs and device/diagnostic development—a selling point for integrated clinical delivery services across therapeutic areas.

Global Reach Fortrea operates in over 90 countries with a large investigator network and ~19,000 staff, suggesting Chiltern can leverage established global trial management, site access, and cross-border efficiencies to win international studies and faster patient enrollment.

Tech-Enabled Trials Recent tech initiatives like Fortrea Intelligent Technology and a modern tech stack (OpenAI Sora, Azure, Zoom, and other tools) signal opportunities to offer advanced trial solutions, data analytics, remote monitoring, and streamlined trial operations to prospective sponsors.

Financial Momentum With revenue in the mid hundreds of millions and ongoing leadership additions, Chiltern/Fortrea demonstrates financial scale and investment in leadership and governance that can support larger, multi-phase trials and higher-revenue collaborations.

Policy and Partnerships Active executive hires and strategic partnerships (e.g., cell and gene therapy collaboration, general counsel appointment) point to a favorable M&A/partnership landscape and risk management capabilities that can reassure sponsors seeking compliant, scalable CRO partnerships for advanced therapies.